NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing
NurExone CEO Dr. Lior Shaltiel discusses U.S. exosome manufacturing, Mexico expansion, ExoPTEN and plans for a potential U.S. listing.